US2016355505A1PendingUtilityA1
Novel compounds
Est. expiryMar 11, 2031(~4.6 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 37/00A61P 37/08A61P 37/06A61P 43/00A61P 7/00A61P 9/00A61P 29/00A61P 19/02A61P 17/04A61P 17/00A61P 17/02A61P 13/12A61P 19/04C07D 403/12C07D 401/12A61K 31/55A61K 9/0014A61K 45/06C07D 401/14A61K 31/4725
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory diseases and/or allergic conditions, in cancer therapy, specifically heme malignancies, and autoimmune conditions.
Claims
exact text as granted — not AI-modified1 . A compound of formula (I):
wherein:
X is CR 1 or N;
Y is CH, C or N;
R 1 is hydrogen, C 1-6 alkoxy or C 1-6 alkyl;
R 2 is hydrogen, C 1-6 alkoxy, halo, —C(O)C 1-6 alkyl, CN, Halo-C 1-6 alkyl or C(O)NR 4 R 5 ;
R 3 is hydrogen or C 1-6 alkoxy;
R 4 is hydrogen or C 1-6 alkyl;
R 5 is hydrogen or C 1-6 alkyl; and
m and n are integers each independently selected from 1 and 2; or
a salt thereof.Join the waitlist — get patent alerts
Track US2016355505A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.